Evaluation of Safety, Tolerability and Preliminary Efficacy of EHP-101 in Relapsing Forms of Multiple Sclerosis
A Phase IIa, Open-label, Multicentre Dose-Finding Trial in Patients With Relapsing Forms of Multiple Sclerosis (RMS) to Evaluate the Safety, Tolerability and Preliminary Efficacy of EHP-101
Sponsor: Emerald Health Pharmaceuticals
Suspended
Temporary recruitment pause to re-assess the protocol design, specifically the eligibility criteria
Listed as NCT04909502, this PHASE2 trial focuses on Relapsing Forms of Multiple Sclerosis and remains suspended. Sponsored by Emerald Health Pharmaceuticals, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Suspended PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Jun 2022 — Nov 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jun 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Oct 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Emerald Health Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .